ImmunityBio Inc (NASDAQ:IBRX) shares, rose in value on Thursday, March 27, with the stock price up by 20.86% to the previous day’s close as strong demand from buyers drove the stock to $3.36.
Actively observing the price movement in the last trading, the stock closed the session at $2.78, falling within a range of $2.78 and $3.375. The value of beta (5-year monthly) was -0.183. Referring to stock’s 52-week performance, its high was $10.53, and the low was $2.28. On the whole, IBRX has fluctuated by 12.00% over the past month.
With the market capitalization of ImmunityBio Inc currently standing at about $2.87 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 105.24M, with a low estimate of 13.78M and a high estimate of 19.74M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 17.5M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IBRX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IBRX currently trading nearly 15.36% and 8.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.72, while the 7-day volatility ratio is showing 8.40% which for the 30-day chart, stands at 8.27%. Furthermore, ImmunityBio Inc (IBRX)’s beta value is 0.43, and its average true range (ATR) is 0.25.
A comparison of ImmunityBio Inc (IBRX) with its peers suggests the former has fared considerably weaker in the market. IBRX showed an intraday change of 20.86% in last session, and over the past year, it shrunk by -38.24%%.
Data on historical trading for ImmunityBio Inc (NASDAQ:IBRX) indicates that the trading volumes over the past 10 days have averaged 5.74 and over the past 3 months, they’ve averaged 5.98 million. According to company’s latest data on outstanding shares, there are 852.74 million shares outstanding.
Nearly 89.60% of ImmunityBio Inc’s shares belong to company insiders and institutional investors own 9.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 59.54 million shares as on 2025-03-14, resulting in a short ratio of 9.03. According to the data, the short interest in ImmunityBio Inc (IBRX) stood at 1871.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 56.96 million. The stock has risen by 31.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IBRX stock heading into the next quarter.
